Eli Lilly plans to acquire Morphic Therapeutics, a biotechnology company, for $3.2 billion in an all-cash deal. Morphic,…

This article Eli Lilly is making a game-changing move in healthcare with a $3.2 billion acquisition! 💊 appeared first on Guerilla Stock Trading.

The FDA approved a new Alzheimer’s drug, Kisunla, from Eli Lilly, following unanimous recommendation by an expert panel.…

This article Finally! A New Hope for Alzheimer’s Patients – FDA Approves Kisunla 🙌 appeared first on Guerilla Stock Trading.

Positive Clinical Trial Results Propel Altimmune Altimmune (ALT) has recently caught the attention of investors, with its stock…

This article Altimmune’s obesity drug shows jaw-dropping 15.6% weight loss – could this be the future of weight loss? 💊 appeared first on Guerilla Stock Trading.

Amphastar Pharmaceuticals is experiencing a bullish trend reversal following their strong Q1 2024 financial performance. The company reported…

This article Amphastar’s product portfolio is thriving – discover how this pharma giant is conquering new markets! appeared first on Guerilla Stock Trading.

Innovation knows no bounds, especially in the realm of pharmaceuticals. Eli Lilly (LLY), a stalwart in the industry,…

This article Revolutionizing Drug Discovery: The Rise of AI in Pharmaceutical Innovation appeared first on Guerilla Stock Trading.

Eli Lilly has reported a strong performance in the first quarter of 2024, continuing the momentum from 2023…

This article Mounjaro & Zepbound Drive Eli Lilly’s Revenue Sky-High in Q1 appeared first on Guerilla Stock Trading.

In a bold move poised to reshape the landscape of diabetes and obesity treatment, Eli Lilly announced its…

This article Eli Lilly’s Ambitious Expansion Plan: A Game-Changer for GLP-1 Medicines appeared first on Guerilla Stock Trading.

In a groundbreaking clinical trial conducted by Novo Nordisk four years ago, a drug called semaglutide demonstrated remarkable…

This article The Obesity Drug Revolution: A New Era in Weight Loss Treatment appeared first on Guerilla Stock Trading.

In the bustling world of stock markets, where companies are often categorized by their primary focus, there are…

This article Unveiling Schrodinger: More Than Just an AI Stock appeared first on Guerilla Stock Trading.

In the fast-paced world of biotech, Schrodinger Inc. (NASDAQ: SDGR) stands out as a company at the forefront…

This article Schrodinger: Pioneering Drug Discovery with AI and Physics-based Modeling appeared first on Guerilla Stock Trading.

In the ongoing battle against obesity, pharmaceutical companies are constantly striving to develop more effective treatments. Novo Nordisk,…

This article A Breakthrough in Obesity Treatment: Novo Nordisk’s Experimental Pill Shows Promise appeared first on Guerilla Stock Trading.

This article Exploring the Dynamic Landscape of the Radiopharmaceutical Market appeared first on Guerilla Stock Trading.

This article Harnessing AI in Biotechnology: A New Era of Drug Discovery and Development appeared first on Guerilla Stock Trading.

This article Eli Lilly’s Strong Finish to 2023 appeared first on Guerilla Stock Trading.

This article Eli Lilly’s Strong Q4 Performance Driven by Zepbound and Mounjaro appeared first on Guerilla Stock Trading.

This article The Week Ahead: Earnings, Economic Data, and Key Events appeared first on Guerilla Stock Trading.

This article Michael Yee’s Positive Outlook for the Biotechnology Sector in 2024 appeared first on Guerilla Stock Trading.

This article Eli Lilly Emerges as a Rising Star in the Pharmaceutical Industry appeared first on Guerilla Stock Trading.

This article Eli Lilly’s Ambitious $2.5 Billion Investment in Germany to Meet Growing Demand for Diabetes and Obesity Therapies appeared first on Guerilla Stock Trading.

This article The Global Anti-Obesity Medications Market: A Growing Opportunity appeared first on Guerilla Stock Trading.